Pancreatic adenocarcinoma-associated polymyositis treated with corticosteroids along with cancer specific treatment: case report

Syrios, John; Kechagias, Georgios; Xynos, Ioannis; Gamaletsou, Maria N.; Papageorgiou, Alexia; Agrogiannis, George; Tsavaris, Nicolas

doi:10.1186/1471-230x-11-33

Cited by 13 publications

(13 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified 12 cases of radiation recall gemcitabine myositis, defined as myositis developing within a radiation port (Table 1) [7][8][9][10][11][12][13][14][15][16][17], and eight patients with gemcitabine-induced multifocal myositis in patients who either had not been irradiated or who developed the symptoms outside of the radiation portal (Table 2) [1,[18][19][20][21][22]. Therefore, gemcitabine appears to be associated with myositis.…”

Section: Discussionmentioning

confidence: 98%

Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review

et al. 2011

View full text Add to dashboard Cite

Gemcitabine potential myotoxicity has been described in several cases of radiation recall and in patients treated with gemcitabine alone or in combination with other chemotherapy agents. We report two cases of gemcitabine related myositis identified at our institution, and perform a literature review of cases which meet the criteria for gemcitabine induced myositis associated to either radiation therapy or chemotherapy alone.

show abstract

Section: Discussionmentioning

confidence: 98%

Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Other therapies option include tacrolimus, a calcineurin inhibitor that has proven to be beneficial in patients having a refractory disease with simultaneous use of prednisolone. Mycophenolate mofetil has also been found to be useful in treating refractory cases of polymyositis [28]. Patients with different systems involved must be evaluated by the concerned specialty e.g.…”

Section: Management and Treatmentmentioning

confidence: 99%

Overview on Diagnosis and Management of Polymyositis

Hussein

Almandeil

Alsulami

et al. 2021

JPRI

View full text Add to dashboard Cite

Polymyositis (PM) is an autoimmune disorder; result from abnormal activation of cytotoxic T lymphocytes (CD8 cells) and macrophages against muscular antigens as well as the strong extrafusal muscular expression of major histocompatibility complex class 1 causing damage to the endomysium of the skeletal muscles. Polymyositis develops over the months as compared to inclusion body myositis (IBM), which is a slowly progressive chronic myopathy developing in older individuals over a period of months to years with more severe symptoms. Many patients require treatment for many years. Polymyositis affects the distal musculature of the esophagus in the late stage of disease in up to 70% of the patients leading to the inability to swallow, as well as regurgitation problems that can cause aspiration pneumonia. The principal goals of therapy are to improve strength and improve physical functioning. Many patients require treatment for several years. The 5-year survival rate for treated patients is in the order of 95%. Up to one-third of PM patients may be left with some degree of residual muscle weakness.

show abstract

“…Other skin signs reported in pancreas-related conditions or part of a syndrome with pancreatic involvement are summarized in Table 2 [ 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 ]. Some of them are presented as rare case reports or small case series; others such as Trousseau’s syndrome may be encountered relatively commonly in clinical practice.…”

Section: Cutaneous Manifestations In Pancreatic Diseasesmentioning

confidence: 99%

Cutaneous Manifestations in Pancreatic Diseases—A Review

Miulescu

Balaban

Şandru

et al. 2020

JCM

View full text Add to dashboard Cite

Pancreatic pathology, comprising acute and chronic pancreatitis, autoimmune pancreatitis and pancreatic neoplasms, primarily presents with gastrointestinal symptoms and signs; however, it is well recognized that it can also associate a wide range of extra-digestive features. Among these systemic manifestations, cutaneous involvement plays an important role both as a diagnostic clue for the pancreatic disease itself and serving as a prognostic factor for the severity of the condition. Recognition of these cutaneous signs is, however, far from being satisfactory, all the more as some of them are relatively rare. In the current review, we discuss skin involvement in pancreatic diseases, referring to pancreatic panniculitis, cutaneous hemorrhagic manifestations, skin metastasis, acanthosis nigricans, livedo reticularis, necrolytic migratory erythema and cutaneous fistula. We highlight the clinical characteristics, treatment and prognostic value of these lesions. Better awareness among medical specialties other than dermatology is needed for detection of the skin clues associated with pancreatic pathology.

show abstract

Pancreatic adenocarcinoma-associated polymyositis treated with corticosteroids along with cancer specific treatment: case report

Cited by 13 publications

References 12 publications

Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review

Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review

Overview on Diagnosis and Management of Polymyositis

Cutaneous Manifestations in Pancreatic Diseases—A Review

Contact Info

Product

Resources

About